American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome
Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized
by abdominal pain and/or discomfort associated with altered defecation. 1 Other common …
by abdominal pain and/or discomfort associated with altered defecation. 1 Other common …
Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome
E Raschi, F De Ponti - Expert opinion on drug metabolism & …, 2014 - Taylor & Francis
Introduction: Lubiprostone acts locally (apical membrane of human intestinal epithelial cells)
as a highly selective type-2 chloride channel activator. It was approved in the USA for …
as a highly selective type-2 chloride channel activator. It was approved in the USA for …
Existing FDA pathways have potential to ensure early access to, and appropriate use of, specialty drugs
Specialty drugs are notable among prescription drugs in that they offer the possibility of
substantial clinical improvement, come with important risks of adverse events and mortality …
substantial clinical improvement, come with important risks of adverse events and mortality …
Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story?
M Grover, M Camilleri - Clinical Gastroenterology and Hepatology, 2014 - cghjournal.org
Over the past decade, a greater understanding of the pathophysiology of diarrhea-
predominant irritable bowel syndrome (IBS-D) has resulted in exploration of newer treatment …
predominant irritable bowel syndrome (IBS-D) has resulted in exploration of newer treatment …